Authors describe two cases of bone lesions ("brown" tumour) secondary to hyperparathyroidism in whom incisional biopsy gave an incorrect diagnosis. The first case was a patient with a lesion of the right femur diagnosed as aneurismal cyst and; the second case was a patient with an isolated lesion of the distal metaphysic of right humerus firstly diagnosed as giant cells tumour. Treatment of the first case was resection and diaphyseal spacer, and the correct diagnosis of brown tumour was performed for the multiple tibial localizations appeared six months later. The second case was diagnosed as affected by a brown tumour secondary to hyperparathyroidism on the basis of clinical history and laboratory analysis. Both diagnoses were firstly incorrect and would have brought to an inadequate treatment with consequences on patients quality life. Differential diagnosis is discussed and the importance to evaluate all the diagnostic data to formulate a correct diagnosis is stressed.

Download full-text PDF

Source

Publication Analysis

Top Keywords

secondary hyperparathyroidism
12
tumour secondary
8
case patient
8
second case
8
correct diagnosis
8
brown tumour
8
isolated bone
4
bone lesion
4
lesion secondary
4
hyperparathyroidism diagnostic
4

Similar Publications

Primary Hyperparathyroidism induces Erythropoietin resistance through FGF23.

Eur J Endocrinol

March 2025

Department of Medicine, Division of Nephrology and Hypertension, University Hospitals of Geneva, Geneva, Switzerland.

Introduction: Primary hyperparathyroidism (PHPT) often causes hypercalcemia and complications requiring parathyroidectomy (PTX). Anemia affects 15-50% of PHPT patients, but its mechanisms remain unclear. While parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) contribute to anemia in secondary hyperparathyroidism (SHPT) through erythropoietin (EPO) resistance and bone marrow fibrosis, their roles in PHPT are less defined.

View Article and Find Full Text PDF

Per- and Poly-fluoroalkyl substances (PFASs) are among the substances that have been widely employed across the world due to their distinct features. These chemicals' great stability in the environment and capacity to be released from consumer goods have demonstrated their existence in all matrices. Additionally, the world's attention has been drawn to these substances' direct relation to human health in recent years.

View Article and Find Full Text PDF

Secondary hyperparathyroidism (SHPT) is a common complication in chronic kidney disease patients, necessitating effective management to prevent adverse outcomes. This study evaluates the efficacy of surgical intervention in achieving biochemical balance in SHPT patients resistant to medical therapy. The study includes 36 patients with SHPT who underwent subtotal parathyroidectomy following failed medical management.

View Article and Find Full Text PDF

Fgf23 expression increases atherosclerotic plaque burden in male ApoE deficient mice.

Atherosclerosis

February 2025

Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden.

Introduction: Components of both the innate and adaptive immune system impact on arterial walls in atherosclerosis. Fibroblast growth factor-23 (FGF23) is a phosphate regulating hormone linked to cardiovascular disease (CVD) in patients with and without chronic renal disease. However, it remains controversial whether FGF23 is merely a biomarker or contributes to CVD.

View Article and Find Full Text PDF

Perirenal fat differs in patients with chronic kidney disease receiving different vitamin D-based treatments: a preliminary study.

BMC Nephrol

March 2025

Grupo de Investigación en Enfermedades Cardiorrenales y Metabólicas, Departamento de Medicina y Cirugía, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, 46115, Spain.

Introduction: Chronic kidney disease (CKD) patients show high rates of cardiovascular disease (CVD) and mortality. In the general population, obesity, hypertension, and diabetes are known as the classical CVD risk factors. However, CKD patients have other predisposing CVD factors more associated with bone and mineral metabolism disorders (BMD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!